Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 2003 Apr 23-30;289(16):2094-103. PubMed.

AlzBiomarker Database

Meta-Analysis

Curated Study Data

Biomarker
(Source)		 Cohort
(N)		 Measurement
Mean ± SD		 Method;
Assay Name;
Manufacturer		 Diagnostic
Criteria
Aβ42
(CSF)		 AD
(131)		 183 ± 121
pg/mL		 ELISA;
Other/Not Specified;
In-house		 McKhann et al., 1984; 1993
Aβ42
(CSF)		 CTRL-
CNC
(72)		 491 ± 245
pg/mL		 ELISA;
Other/Not Specified;
In-house
tau-total
(CSF)		 AD
(131)		 587 ± 365
pg/mL		 ELISA;
Innotest;
Innogenetics		 McKhann et al., 1984; 1993
tau-total
(CSF)		 CTRL-
CNC
(72)		 224 ± 156
pg/mL		 ELISA;
Innotest;
Innogenetics

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

News

  1. Diagnosis of AD—Does Spinal Fluid Hold the Key?
  2. St. Louis: Biomarkers Pre-dementia—Like eFAD, Like LOAD?
  3. In Healthy Brains, Does Aβ Really Matter?
  4. CSF Testing for AD: Single-center Bliss, Multicenter Woe?
  5. Alzheimer Activism: How To Modernize Clinical Trials?

Research Timeline Event

  1. CSF Aβ, CSF Aβ/tau ratio predicts decline in cognitively normal elderly and FAD mutation carriers

AlzBiomarker

  1. AD vs CTRL : Aβ42 (CSF)
  2. CTRL vs AD : Aβ42 (CSF)
  3. AD vs CTRL : tau-total (CSF)
  4. CTRL vs AD : tau-total (CSF)